More information about Neal L. Weintraub, MD.
Neal L. Weintraub, M.D., a native of Albany, Georgia, graduated from Tulane University School of Medicine in 1984. He completed clinical training in Internal Medicine at Emory University and the University of Illinois and undertook a combined research/clinical Cardiovascular Fellowship at St. Louis University from 1991-1995. He joined the faculty at the University of Iowa College of Medicine in 1995, rising to the rank of Professor of Medicine in 2005 and serving as Interim Division Director of Cardiovascular Diseases from 2003-2005. In 2006, he was recruited to the University of Cincinnati College of Medicine as the Stonehill Professor of Medicine and Director, Division of Cardiovascular Diseases. In June of 3013, Dr. Weintraub was recruited to Georgia Regents University/Medical College of Georgia, where he holds the title of Kupperman Eminent Scholar in Cardiovascular Medicine and serves as Professor of Medicine and Associate Director of the Vascular Biology Center.
Dr. Weintraub’s laboratory is focused on vascular biology research with emphasis on oxidative stress, inflammation, and obesity. In particular, his work has advanced the understanding of the role of inflammation and oxidative stress in the pathogenesis of aortic aneurysm disease. He has been NIH funded since 1997 and currently is a principal investigator on two R01 grants. Dr. Weintraub served on the NIH AICS study section from 2008-2013 and was Chairman from 2011-2013. He has served on the editorial board of the journal Arteriosclerosis, Thrombosis and Vascular Biology since 2000 and was named Associate Editor of Translational Research in 2014.
As a clinical cardiovascular physician, Dr. Weintraub treats patients with a variety of cardiovascular disorders and has been ranked among the Best Doctors in America for seven consecutive years. He also conducts clinical research in stem cell therapy, heart failure, and remote cardioprotection. Dr. Weintraub is Co-Founder and Chief Medical Officer of Cardioception, LLC., a biotech company established in 2010 that is utilizing the skin’s natural protective functions to develop innovative therapies for limiting heart damage in the setting of a heart attack. He chaired an American Heart Association Writing Committee that developed a scientific statement on acute treatment of heart failure in 2010. Also, he served as President of the Central Society for Clinical Research, an academic medical society in the Midwest, during 2013.